Kori V K, Patel K S
Department of Kaumarbhritya, Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India.
Ayu. 2020 Oct-Dec;41(4):218-224. doi: 10.4103/ayu.AYU_206_20. Epub 2022 Jun 3.
Anemia is a public health problem worldwide, and its prevalence in India is higher than any other south asian countries. Iron deficiency anemia (IDA) is having larger share out of all types of anaemia's. Symptomatology of IDA resembles with dominant variety of . (PV) and (PM) mentioned in Ayurveda are being used in clinical practice since long.
To assess the efficacy of and compare its clinical efficacy with in the management of ws.r. iron deficiency anemia in children.
Present clinical study was a randomized trial for management of iron deficiency anemia aged 2-16 years. Out of total 91 patients enrolled, 60 completed the study and divided into two groups. In group A, (trial drug) and in group B, in the management of ws.r. iron deficiency anemia in children. (standard drug) were given to 30-30 patients respectively for a duration of 90 days in age specific doses. Patients were assessed by clinical signs and symptoms of and investigation parameters like complete blood count, serum iron, serum ferritin and total iron binding capacity (TIBC) on baseline and after 90 days of treatment. Statistical analysis was carried out by Sigma Stat software.
On comparison, highly significant difference was found between two groups in subjective parameters such as (pallor), (weakness), (palpitation), (periorbital oedema), (leg cramps) and (breathlessness) whereas objective and saturation percentage except serum ferritin.
The study revealed that, both the drugs; and were equally effective in the management of IDA so, it could be concluded that , can be used as mineral-free, safe, easily obtainable, palatable, cost-effective alternative drug of choice in alternative of in iron deficiency anemia in children.
贫血是一个全球性的公共卫生问题,其在印度的患病率高于任何其他南亚国家。缺铁性贫血(IDA)在所有类型的贫血中占比更大。IDA的症状与阿育吠陀中提到的主要类型的真性红细胞增多症(PV)和真性红细胞减少症(PM)相似,长期以来一直在临床实践中使用。
评估[药物名称未明确]的疗效,并将其在儿童缺铁性贫血管理中的临床疗效与[药物名称未明确]进行比较。
本临床研究是一项针对2至16岁缺铁性贫血管理的随机试验。在总共纳入的91名患者中,60名完成了研究并分为两组。A组给予[药物名称未明确](试验药物),B组给予[药物名称未明确](标准药物),分别给予30名患者,按年龄特定剂量给药90天。通过贫血的临床体征和症状以及全血细胞计数、血清铁、血清铁蛋白和总铁结合力(TIBC)等检查参数在基线和治疗90天后对患者进行评估。使用Sigma Stat软件进行统计分析。
比较发现,两组在主观参数如面色苍白、虚弱、心悸、眶周水肿、腿部痉挛和呼吸急促等方面存在高度显著差异,而客观参数和除血清铁蛋白外的饱和度百分比方面[描述不清晰]。
研究表明,两种药物[药物名称未明确]和[药物名称未明确]在IDA管理中同样有效,因此可以得出结论,[药物名称未明确]可作为无矿物质、安全、易于获得、可口、具有成本效益的替代药物,替代[药物名称未明确]用于儿童缺铁性贫血的治疗。